Pathway enrichment involves cytokine‐cytokine receptor pathways, including tyrosine kinase receptor activity and phosphokinase receptor and androgen receptor pathway activation; TKIs are currently the primary treatment for CML patients (Arrigoni et al., 2018). Here, NTRK1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.